Skip to main content
Home Home

User account menu

Log in

Main navigation

  • Home
  • Topics
    • Biological medicines
    • Cardiovascular disease
    • Equity
    • Focus medicines
    • Gout
    • Type 2 diabetes
  • Resources
    • All education/search
    • Events
    • HAH Bulletins
    • Podcasts
    • Recorded webinars
    • Reflection activities
    • Resource hubs
    • Videos
  • EPiC dashboard
    • Go to EPiC
    • Join EPiC
    • EPiC FAQ
    • EPiC Demo
    • About EPiC
    • Win with EPiC!
  • News
    • That's Interesting
    • From The Team

Education

  1. Home
  2. Search

The hub for all your learning resources.

Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.

Parkinson's Disease

Selegiline is being discontinued: What does this mean for your patients?

8 minutes to Read

Patients can no longer be started on funded selegiline. Patients who were on selegiline prior to 1 August 2021 will need their prescriptions endorsed to receive subsidised supplies. An alternative MAO-B inhibitor, rasagiline, may be a suitable agent for new patients or those transitioning from selegiline.

This resource provides a timeline for the changes and information about transitioning patients from selegiline. Advice on prescribing rasagiline is also included.

Contributor
He Ako Hiringa
14 September 2021
  • Selegiline rasagiline

Dulaglutide: the long-awaited new agent to treat type 2 diabetes

78 minutes to Watch

In this webinar, Dr Ryan Paul discusses the newly-funded type 2 diabetes medication dulaglutide, and provides advice on when and how to use it.

Contributor
Dr Ryan Paul
2 September 2021
  • Diabetes
  • Recorded webinar

Can you say dulaglutide?

Dulaglutide is available from 1 September, but do you know how to pronounce it? Listen to our quick guide for help.

Contributor
He Ako Hiringa
30 August 2021
  • Videos
  • Diabetes
Dulaglutide Algorithm

Initiating treatment with dulaglutide: Algorithms, notes and talking points

15 minutes to Delve

From 1 September and when clinically indicated, dulaglutide can be started in adult patients with type 2 diabetes using the steps shown in this resource.

Talking points, relevant for all patients starting dulaglutide, are provided along with two algorithms and accompanying prescribing notes.

Contributor
Brendan Duck, Ryan Paul
25 August 2021
  • Diabetes
  • Equity
Image of a flowchart

Initiating treatment with empagliflozin: Algorithms, notes and talking points

15 minutes to Delve

When clinically indicated, empagliflozin can be started in adult patients with type 2 diabetes using the steps shown in this resource (updated 24 Aug 2021).

Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk. 

Contributor
Brendan Duck, Ryan Paul
24 August 2021
  • Diabetes
  • Equity

Heart failure therapy: from past to present

60 minutes to Watch

In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.

Contributor
Dr Raewyn Fisher
24 August 2021
  • CVD
  • Recorded webinar
Bulletin #6

Considering the new T2D agents

1 minute to Read

When initiating either empagliflozin or dulaglutide, the newly funded second-line type 2 diabetes agents,1 choice is based primarily on predominant comorbidities, clinical features and tolerability.

Administration route is an additional factor; dulaglutide is a once-weekly, subcutaneous injection and empagliflozin is a daily tablet. Patient factors are also important, and the contraindications and adverse effects profiles differ. 

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
17 August 2021
  • HAH Bulletins
  • Diabetes
Image of a molecular structure

Introduction to biological medicines

4 minutes to Read + 15 minutes to Explore

Biological medicines are already used in Aotearoa New Zealand and with more being developed internationally, it’s important that health professionals feel comfortable prescribing, dispensing, and supporting patients to use them.

We’ve highlighted five key aspects of these medicines in an article and a series of short animated videos. After completing each section, you can take a short quiz to test your learning.

Contributor
He Ako Hiringa
11 August 2021
  • Biological medicines
  • Videos
ECG

Switching blood pressure medications – it’s time to break the cilazapril habit

3 minutes to Read

Last year, cilazapril with hydrochlorothiazide was discontinued, and now cilazapril alone is no longer funded for new patients. Consultant cardiologist Chris Ellis discusses what to do when patients with hypertension run out of their supply of these medications

Contributor
Chris Ellis
2 August 2021
  • CVD
Bulletin #5

Cilazapril unplugged – what alternatives?

1 minute to Read

Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2

Read the HAH Bulletin to find out more.

Contributor
He Ako Hiringa
19 July 2021
  • HAH Bulletins
  • CVD
The 5 As - availability, accessibility, affordability and appropriateness

The five drivers of medicine access equity

1 minute to Read

Pharmac has identified five key drivers of medicine access equity in New Zealand. Read on to learn about the drivers and how you can implement them in your place of work. 

13 July 2021
  • Equity
person leaping across a void

Starting injectable medicine: How to prepare your T2D patients

7 minutes to Read

Dulaglutide, a once-weekly injectable medicine, will soon be available for second-line treatment of type 2 diabetes. As most people with type 2 diabetes will require an injectable therapy at some stage, it is important to build acceptability early in the patient journey.

Contributor
Louise Roche Farmer
29 June 2021
  • Diabetes

Pagination

  • « First First page
  • ‹ Previous Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next › Next page
  • Last » Last page
Home Home

Contact Us

11 Omana Road, Milford Auckland NZ, 0620

PO Box 31905, Milford Auckland NZ, 0741

Support

09 488 4286

admin@akohiringa.co.nz

(9-5pm Mon-Fri)

Contact us

About us

Terms & Policies

  • Conditions for Use
  • Privacy Policy

Supported by

Pharmac

© Matui Limited. All rights reserved.

Developed by Matui Limited and brought to life by Communica.